Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05956418RecruitingPhase 4
Testing centhaquine for low-blood-pressure shock patients
This trial studies whether centhaquine is safe and can help treat adults in the emergency room or ICU who have hypovolemic shock (dangerously low blood pressure from low circulating fluid). Participants receive the usual shock care, and the study adds this medicine to see if outcomes improve.
Nellore, Andhra PradeshAges 18 years+ - NCT05944224RecruitingPhase 1/Phase 2
SPH4336 for advanced solid tumors with or without immunotherapy
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Fuzhou, FujianAges 18–75 - NCT05935215RecruitingPhase 3
Switch from anti-C5 shots to iptacopan for aHUS
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
Nanjing, JiangsuAges 18–100 - NCT05925452Recruiting
Genalumab for children with active systemic juvenile arthritis
This trial studies whether a medicine called genalumab can reduce inflammation and improve symptoms in children with active systemic juvenile idiopathic arthritis (sJIA). It also checks how safe the treatment is, including possible side effects.
Beijing, BenjingAges 2–17 - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT05918302RecruitingPhase 3
Compare radiotherapy versus everolimus for lung and thymus tumors
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
Edegem, EdegemAges 18 years+ - NCT05926505RecruitingPhase 2/Phase 3
Anakinra for lingering symptoms after COVID-19
This Phase 2/3 trial studies whether anakinra can improve ongoing (post-acute) COVID-19 symptoms lasting for more than two months. It mainly looks for better safety and symptom improvement in people with specific inflammation and lung-related findings.
JenaAges 18 years+ - NCT05926700RecruitingPhase 2
Testing cadonilimab plus anlotinib for advanced soft tissue sarcoma
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
HangzhouAges 18 years+ - NCT05938712RecruitingPhase 2
Kidney transplant trial using two diabetes medicines safely
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Toronto, OntarioAges 18 years+ - NCT05288179RecruitingPhase 3
Pirfenidone capsules for silicosis or coal dust lung disease
This Phase 3 trial tests whether pirfenidone slows or improves lung damage in people with silicosis or coal worker’s pneumoconiosis. It looks at both effectiveness and side effects, and uses lung function tests and lung scans to track changes over time.
BeijingAges 18–70 - NCT05532813RecruitingPhase 3
Metformin for adult myotonic dystrophy type 1 muscle weakness
This Phase 3 trial tests whether metformin can improve symptoms and safety in adults with genetically confirmed myotonic dystrophy type 1 (DM1). It may help reduce muscle problems, but you must meet specific walking, breathing, heart, and kidney requirements.
GarchesAges 18–70 - NCT05891821RecruitingPhase 2
Balstilimab for relapsed lymphoma after standard treatments failed
This phase 2 study tests balstilimab to see if it can be safe and effective for certain lymphomas that came back or didn’t respond to standard treatment. If you qualify, you’ll be checked closely for side effects and how well your lymphoma responds.
YerevanAges 18 years+ - NCT05895981Recruiting
Sacral nerve stimulation for ulcerative colitis symptoms
This trial tests whether sacral nerve stimulation—a device that sends small electrical signals near nerves in the lower back—can be safe and helpful for ulcerative colitis. It is meant for people whose ulcerative colitis has not improved enough with medicines.
Xi'an, ShaanxiAges 18 years+ - NCT05901818RecruitingPhase 1
Testing a patient’s own stem-cell treatment for Parkinson’s
This Phase 1 study tests whether an “autologous” (from your own body) iNSC-DAP stem-cell treatment is safe and may help symptoms in Parkinson’s disease. It is designed mainly to check safety, while also watching for signs of improvement.
Beijing, Beijing MunicipalityAges 30–85 - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Gilbert, ArizonaAges 18 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT05893888RecruitingPhase 2/Phase 3
Testing three investigational drugs for mouth and lung cancers
This trial tests whether PRV111, PRV211, and PRV131 are safe and work better than expected for certain mouth (lip/oral cavity) cancers and lung cancers. It may help by trying a new approach given directly to the tumor and then monitoring how well it shrinks and how safe it is.
Duarte, CaliforniaAges 18–100 - NCT05741359RecruitingPhase 1
Study of BRL-201 for hard-to-treat aggressive B-cell lymphoma
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
Wuhan, HubeiAges 18 years+ - NCT05547321RecruitingPhase 1
New cancer drug plus immunotherapy for advanced solid tumors
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Boston, MassachusettsAges 18 years+ - NCT05865379Recruiting
Tested eye drops for dry eye relief and safety
This trial studies whether BUFY01 eye drops work better than SVS20 for treating dry eye disease. You may be able to join if you have dry eye symptoms for at least 3 months and meet eye exam score and tear-test requirements.
LeuvenAges 18 years+ - NCT05865002RecruitingPhase 1
Safety and drug test for AUR107 in advanced cancers
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05871970RecruitingPhase 2
TARA-002 treatment for lymphatic cysts in children
This Phase 2 trial tests whether an injected medicine called TARA-002 placed inside lymphatic cysts can safely shrink lymphatic malformations in children. It may help especially when the cysts are mainly in the head, neck, or chest area.
Birmingham, AlabamaAges 6 months–18 years - NCT05865457Recruiting
Testing two eye treatments for dry eye symptoms
This trial compares two different dry-eye eye drops to see which works better and is safe. You may be able to join if you’ve had dry eye for at least 3 months and meet specific eye-test results.
GrazAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.